IBM Faces a Crossroads: Analyst Split and Earnings Test Loom Over Stretched Stock
Published on 07/12/2026 at 03:03 | Redaktion boerse-global.de
Two weeks before IBM’s second-quarter earnings report, the stock finds itself caught between sharply divergent analyst views — and the widening gap is already showing up in price action. While BofA Securities raised its price target to $330 with a “Buy” rating and Jefferies stuck with $320, Susquehanna initiated coverage with a “Neutral” and a $303 target. The latter, arriving precisely as the shares sit 13.8% off their 52-week high, was enough to fuel a 2.28% slide on Friday, closing at €252.40 in Europe.
The sell-off looked sharp on the day, but zooming out paints a calmer picture. Over the past 30 days the stock is still up 6.86%, and year-to-date it has gained 1.51%. The price remains comfortably above both its 50-day moving average of €228.35 and its 200-day line of €237.03, with a relative strength index of 56.4 — neutral with a slight bullish tilt. Still, the annualized 30-day volatility of 43.58% underscores that IBM is trading more like a growth stock than the steady industrial tech name it once was.
The fresh “Neutral” from Susquehanna, a bank that hadn’t previously covered the stock, stands out not for being bearish but for what it signals about market sentiment just ahead of the numbers. The consensus price target among analysts sits at €257.99, barely 2.2% above the current level — a stark contrast to the optimistic U.S. broker targets of $330 to $375. That disconnect raises the stakes for the July 22 report, when IBM will release results for the quarter ended June.
Institutional positioning already hints at nervousness. Advisors Management Group trimmed its IBM stake by 10.5% in the first quarter, selling 3,629 shares to leave 30,869 holdings valued at roughly $7.48 million. Some investors are booking profits after the stock’s strong run from its May low of €181.32 — more than 39% below current levels. Yet others are betting on the long-term software narrative.
Should investors sell immediately? Or is it worth buying IBM?
For the June quarter, analysts expect software revenue of $8.26 billion, an 11.8% increase year-over-year. That growth is central to the “software compounder” thesis that has drawn bulls like Jefferies, which bases its $320 price target on 20 times estimated free cash flow for 2027. But the consulting division remains a wild card, and the broader debate over IBM’s transformation has grown into two opposing narratives.
Bulls point to IBM’s deep roots in regulated industries, its infrastructure focus, and a consulting arm that drives AI adoption. Jefferies argues the company is better positioned for the AI era than the market believes. Bears counter that generative AI could erode IBM’s COBOL modernization revenue, squeeze software margins, and expose a fading infrastructure demand cycle. The “legacy risk” story now competes directly with the company’s ambitions in AI and quantum computing.
On the product front, IBM is trying to widen its addressable market. On July 11 it announced that its z17 and LinuxONE 5 systems would be available in rack-mount configurations for the first time, alongside traditional single-frame models. The compact designs, powered by Telum II processors, aim to solve data center floor-space issues and bring mainframe capabilities to smaller enterprises — a potential new source of recurring revenue. General availability is set for August 12.
IBM at a turning point? This analysis reveals what investors need to know now.
Technically, the stock has room to move in either direction. The 50-day and 100-day averages at €228.35 and €218.67 are well below the current price, keeping the medium-term trend intact. The closer support is the 200-day line at €237.03, only 6.48% away. With the RSI neutral, there is no clear overbought or oversold signal. What matters now is whether the earnings report on July 22 validates the optimistic forecasts from BofA and Jefferies or aligns more with the caution that Susquehanna’s neutral rating and the trimmed institutional positions suggest. The quarter will not just move the stock — it will decide which story about IBM is correct.
Ad
IBM Stock: New Analysis - 12 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
